TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00553852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant GH Saizen (Merck-Serono)
Description: Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant GH Saizen (Merck-Serono)
Description: Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
Study: NCT01479192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: 100mg (2cps/day) for 5 years

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 cpr/day of matched placebo for 5 years
Study: NCT02594774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulative osteopathy
Description: Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
Study: NCT04363918

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: bioelectric stimulation
Description: bioelectric stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bioelectric stimulation
Description: bioelectric stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bioelectric stimulation
Description: bioelectric stimulation
Study: NCT03364517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Predictor score of the imminence of a childbirth (SPIA)
Description: The SPIA score is based on the analysis of 6 types of criteria: panic during the call, the possibility of having a telephone contact with the parturient, the urge to push and if so for how long, the rhythm of the CU, some aggravating factors (history of fast delivery or at home, maternal age between 26 and 35 years, lack of follow-up of pregnancy) and 2 minor factors (nulliparity and the taking of a tocolytic treatment). Each criteria is between 0 to 8, except for the 2 minor criteria for which 7 and 3 points are removed if they are present. This gives a score between -10 and +33, which is weighted according to the admission time estimated at the hospital (30 minutes, 1h and 2h).
Study: NCT02086448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-CPAP

Intervention type: OTHER
Group type: OTHER
Intervention: Sleep hygiene
Description: Information about sleep apnea and healthy sleep. Information about local sleep resources
Study: NCT01461252

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoablation
Description: For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiation
Description: Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
Study: NCT03347344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 50 mg will be administered (per os) twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg will be administered (per os) twice a day
Study: NCT03356899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose bupivacaine 0.5% (8mg)
Description: 8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose bupivacaine 0.5% (10mg)
Description: 10 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.5
Study: NCT02295761

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling (Fb)
Description: Facebook-delivered lifestyle counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling + activity monitor (Fb+Act)
Description: Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
Study: NCT01720329

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Active comparator Arm. XXmls of XXX supplemented with XX of L. rhamnosus GG on a daily basis for six months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: probiotic placebo
Description: Placebo comparator arm -Participants randomized to placebo will receive XXmls of XXX G on a daily basis for 6 months.
Study: NCT03133091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIEB: Patient Intermittent Epidural Boluses
Description: Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCEA: Patient Controlled Epidural Analgesia
Description: Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
Study: NCT04191941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel CAR-T
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells
Study: NCT04543721

Intervention type: DEVICE
Intervention: 24-h-ABPM
Description: 24-h- blood pressure measurement and pulse wave analysis
Study: NCT02046772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine low dose
Description: A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine standard dose
Description: Single intradural standard dose of bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Chloride
Description: A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
Study: NCT02268370

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Study: NCT04505605

Intervention type: OTHER
Intervention: Blood samples
Description: A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.

Intervention type: OTHER
Intervention: Blood samples
Description: A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.

Intervention type: OTHER
Intervention: Blood samples
Description: A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.
Study: NCT01279564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETview TVT endotracheal tube
Description: intubation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endotracheal tube
Description: Intubation
Study: NCT02655419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATM-AVI
Description: Cohort 1:~(Creatinine clearance \> 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance \> 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 500mg infused over 1 hour every 8 hours
Study: NCT00046917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT02425761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventriculoperitoneal shunt insertion surgery
Description: The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventriculoperitoneal shunt insertion surgery
Description: The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
Study: NCT03407183

Intervention type: PROCEDURE
Intervention: intradetrusor injection of botulinumtoxinA (Botox)
Description: intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.
Study: NCT02335749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting System with a Small Area Applicator will be used to deliver treatments.
Study: NCT04102865

Intervention type: DEVICE
Group type: OTHER
Intervention: Negative-Pressure Wound Therapy (NPWT)
Description: Investigational single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 7 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: Negative-Pressure Wound Therapy (NPWT)
Description: Investigational single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 7 days.
Study: NCT02110940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization exercise
Description: The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Physiotherapy
Description: The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
Study: NCT03901053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reaktiv AFO
Description: This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reaktiv AFO
Description: This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PhatBrace AFO
Description: Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PhatBrace AFO
Description: Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
Study: NCT03466125

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Retrospective cohort study
Study: NCT03802565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone
Description: TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone
Description: TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone
Description: TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone
Description: TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06244498

Intervention type: DRUG
Intervention: Tranexamic acid injection
Description: Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.
Study: NCT02277158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: S-1 CCRT
Study: NCT03925584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Standardized music playlist will be played centrally at the subjects head or feet for a period of 20 minutes once during a 12-hour shift for 14 days or until mechanical ventilation has been discontinued, whichever is first
Study: NCT02664922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1 general anesthesia group for VT ablations and afib procedures.
Study: NCT02806544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20mg by mouth daily
Study: NCT00073892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: 250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
Study: NCT01334580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Pain and Opioid Dependence
Description: CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Drug Counseling
Description: Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
Study: NCT02149316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC+RIPostC
Description: Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
Study: NCT01451697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: A computerized cognitive remediation program focused on attentional training will be used.
Study: NCT02149316

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control
Description: a deflated cuff placed on the right upper arm
Study: NCT03160222

Intervention type: OTHER
Group type: OTHER
Intervention: Body Composition Measurements
Description: Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
Study: NCT01157000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
Study: NCT00759057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Pedicle Screw System
Description: Implantation of Posterior Pedicle Screw System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Pedicle Screw System
Description: Implantation of Posterior Pedicle Screw System
Study: NCT04003545

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LED Photobiomodulation
Description: A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LED Photobiomodulation
Description: For the placebo group, the procedures will be the same, however the LED equipment will remain off.
Study: NCT01319240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
Study: NCT03605940

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methoxsalen + ECP device
Description: 2 sessions per week during 4 weeks and 1 session per week during 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: 2 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: 2 mg/kg/day
Study: NCT01523015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative chemo- and chemoradiotherapy
Description: 2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection
Description: The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
Study: NCT00642109

Intervention type: PROCEDURE
Group type: OTHER
Intervention: midurethral sling procedure
Description: quality of life, voiding dysfunction

Intervention type: PROCEDURE
Group type: OTHER
Intervention: midurethral sling procedure
Description: quality of life, voiding dysfunction

Intervention type: PROCEDURE
Group type: OTHER
Intervention: midurethral sling procedure
Description: quality of life, voiding dysfunction
Study: NCT04197895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation with APRF
Description: Socket preservation with APRF , A-PRF membranes were implanted into the extraction socket following tooth extraction. One entire A-PRF membrane would be placed at the base of the extraction socket and another A-PRF membrane will cover the extraction site then suturing will be done .Venous blood will be collected via venipuncture of the forearm with a butterfly needle into at least 10 mL sterile glass vacuum tube. The blood sample will be immediately centrifuged at 1,300 rpm (200 x g) for 8 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: natural healing
Description: after atraumatic extraction , the socket will be left for natural healing after suturing
Study: NCT00615979

Intervention type: DEVICE
Intervention: Miniature echo machine
Description: Images captured and real-time and store-and-forward file transfers performed
Study: NCT02595281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Serum samples are collected:~* at each neoadjuvant chemotherapy cycle~* before surgery~* at each adjuvant chemotherapy cycle~* at each injection of bevacizumab as maintenance therapy~* stop at the progression or after 24 months post chemotherapy